Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : to report first quarter 2019 results on 14 May 2019

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2019 | 09:54am EDT

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2019. The conference call will be held in English.

Conference call details

Date: Tuesday, 14 May 2019

Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)

From Germany: +49 69 201 744 220

From France: +33 170 709 502

From Italy: +39 02 3600 6663

From the UK: +44 20 3009 2470

From the USA: +1 877 423 0830

Access Code: 35899832#

A simultaneous slide presentation for participants dialling in via phone is available at https://webcasts.eqs.com/evotec20190514/no-audio.

Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.

A replay of the conference call will be available for 24 hours and can be accessed in Europe by dialling +49 69 20 17 44 222 (Germany) or +44 20 3364 5150 (UK) and in the USA by dialling +1 844 307 9362. The access code is 315534322#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact:

Tel: +49. (0)40.560 81-255

Fax: +49. (0)40.560 81-333

Web: www.evotec.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC AG
05:46aEVOTEC : Resolutions of the Annual General Meeting 2019 of Evotec SE
AQ
06/19EVOTEC : Resolutions of the annual general meeting 2019 of evotec se
EQ
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
05/31EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
05/31EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
More news
Financials (€)
Sales 2019 414 M
EBIT 2019 73,4 M
Net income 2019 53,5 M
Finance 2019 6,17 M
Yield 2019 -
P/E ratio 2019 66,18
P/E ratio 2020 64,72
EV / Sales 2019 8,76x
EV / Sales 2020 7,63x
Capitalization 3 637 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,5 €
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG39.76%3 664
IQVIA HOLDINGS INC32.77%26 223
LONZA GROUP31.41%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION33.46%17 061
EXACT SCIENCES CORPORATION83.36%13 037